SAB BIO wins FDA Fast Track for SAB-142 in Stage 3 type 1 diabetes

SAB Biotherapeutics has secured Fast Track designation for its human anti-thymocyte immunoglobulin SAB-142, with trial enrolment expected to complete by end of 2026.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A brightly lit, modern medical imaging room contains a large CT scanner with a patient table and head cradle, large windows with potted plants, and medical carts with monitors.

SAB Biotherapeutics has announced that the US Food and Drug Administration has granted Fast Track designation to SAB-142, its fully human anti-thymocyte immunoglobulin candidate, for the treatment of new-onset Stage 3 type 1 diabetes. The Miami-based, Nasdaq-listed company said the designation reflects the FDA's acknowledgement that SAB-142 has the potential to address a serious unmet medical need in a population with few disease-modifying options.

Fast Track status allows more frequent FDA interactions during development and makes a therapy eligible for rolling review, meaning the agency can assess sections of a marketing application as they are completed rather than waiting for the full submission. It does not guarantee approval or accelerate clinical timelines directly.

The SAFEGUARD and PRISE-hATG studies

SAB-142 is currently the subject of two parallel clinical programmes. The company-sponsored SAFEGUARD study is a registrational Phase 2b trial enrolling people within 100 days of a Stage 3 T1D diagnosis. SAB BIO said enrolment is expected to close in the fourth quarter of 2026, with topline data anticipated in the second half of 2027. Separately, an investigator-led Phase 3 study called PRISE-hATG is designed to evaluate SAB-142 in patients from 100 days to two years after diagnosis, broadening the potential treatment window.

Chief executive Samuel J. Reich said the designation represented "meaningful progress" toward the company's goal of bringing SAB-142 to patients as quickly as possible. The company is positioning SAB-142 as potentially disease-modifying, aiming to delay or prevent progression rather than simply managing symptoms.

Market context and competitive landscape

The Stage 3 T1D space has attracted significant regulatory and commercial attention since the FDA's 2022 approval of teplizumab, marketed by Sanofi as Tzield, the first disease-modifying therapy approved for delaying onset of clinical T1D. Teplizumab is a monoclonal antibody targeting CD3 on T cells. SAB-142 takes a different mechanistic approach as a polyclonal human immunoglobulin, which the company argues may offer a broader immunomodulatory effect.

The competitive field also includes candidates from Provention Bio and several academic consortia investigating combination immunotherapy regimens under the TrialNet network. Investors will note that the T1D population at Stage 3 is relatively small and that commercial uptake of teplizumab has so far been modest, raising questions about market access, pricing, and the willingness of payers to fund preventive biologics at scale.

SAB BIO's platform technology relies on genetically engineered transchromosomic cattle to produce human immunoglobulin G at scale, avoiding the need for human donors or convalescent plasma. This manufacturing approach, while novel, introduces supply chain and regulatory questions that the company will need to address as it moves toward a potential biologics licence application. Topline SAFEGUARD data in the second half of 2027 will be the programme's most significant near-term catalyst.

Sector

Topic

Geography